Tumor Necrosis Factor Inhibitor Drugs Market

A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.

Tumor Necrosis Factor Inhibitor Drugs Market contains market size and forecasts of Tumor Necrosis Factor (TNF) Inhibitor Drugs in Global, including the following market information:

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Tumor Necrosis Factor (TNF) Inhibitor Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Humira Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Necrosis Factor (TNF) Inhibitor Drugs include AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., Novartis International AG, Pfizer, Inc. and Merck & co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Tumor Necrosis Factor (TNF) Inhibitor Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Segment Percentages, by Type, 2021 (%)

• Humira
• Enbrel
• Remicade
• Simponi/Simponi Aria
• Cimzia
• Biosimilars

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Segment Percentages, by Application, 2021 (%)

• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Crohn?s Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Others

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Tumor Necrosis Factor (TNF) Inhibitor Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Tumor Necrosis Factor (TNF) Inhibitor Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• UCB S.A.
• Novartis International AG
• Pfizer, Inc.
• Merck & co., Inc.